Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tenapanor in Maintenance Hemodialysis Patients
Sponsor: Huashan Hospital
Summary
The investigators hypothesize that Tenapanor can improve serum phosphorus control and regulate intestinal metabolism in maintenance hemodialysis patients without increasing the risk of severe gastrointestinal adverse events. Therefore, this study intends to take maintenance hemodialysis patients with hyperphosphatemia as the research object, prospectively observe patients receiving Tenapanor as part of their routine care, and clarify the real-world efficacy of Tenapanor for phosphorus management and its impact on intestinal metabolism in these patients.
Official title: Evaluation of the Real-World Efficacy of Tenapanor and Its Effects on Intestinal Metabolism in Patients Undergoing Maintenance Hemodialysis
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
70
Start Date
2026-09-23
Completion Date
2027-12-15
Last Updated
2026-10-20
Healthy Volunteers
No
Interventions
Tenapanor
Tenapanor is an oral sodium-hydrogen exchanger isoform 3 (NHE3) inhibitor, administered at doses of 10-50 mg once or twice daily, titrated per clinical judgment, for the management of hyperphosphatemia in maintenance hemodialysis patients over an 8-week study period.
Locations (1)
Huashan hospital, Fudan university
Shanghai, Shanghai Municipality, China